

Q1. In the last three months, how many patients have been treated by your haemophilia centre with the following products?

- Advate
- Adynovi
- Elocta
- Esperoct
- Factor Eight Inhibitor Bypass Activity (FEIBA)
- Hemlibra
- Jivi
- NovoEight
- NovoSeven RT
- Obizur
- Refacto AF

No products issued within the last three months

Q2. In the last three months, how many patients were treated with the following products for severe Haemophilia A ONLY?

- Advate
- Adynovi
- Elocta
- Esperoct
- Factor Eight Inhibitor Bypass Activity (FEIBA)
- Hemlibra
- Jivi
- NovoEight
- NovoSeven RT
- Obizur
- Refacto AF

No products issued within the last three months

Q3. For patients treated with Hemlibra in the last three months, please provide

- The number of haemophilia A patients with inhibitors
- The number of severe haemophilia A patients with inhibitors

Not applicable. Moderate and severe patients are managed at Cardiff Haemophilia Centre

Q4. How many haemophilia A patients are registered with your centre, and how many of these patients are classified as exhibiting mild, moderate, or severe disease.

The Health Board has:

15 patients registered with haemophilia A

Mild 15
Moderate 0
Severe 0